Global RNA Therapeutics Market By Technology (RNA Interference, and Antisense RNA), By Route of Administration (Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Topical Delivery and Others), By Indications (Oncology, CVDs, Respiratory Disorders, Neurological Disorders, Infectious Disorders and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

The Global RNA Therapeutics Market accounted for US$ 1.35 billion in 2020 and is estimated to be US$ 2.77 billion by 2030 and is anticipated to register a CAGR of 7.50%.

RNA Therapeutics are a rapidly growing class of pharmaceuticals that will accelerate the development of new treatments, enable personalised therapy, and render the term "undruggable" obsolete. The first RNA medications have been approved, and a large number of others are in the works. We are in the midst of a therapeutic revolution unseen since the introduction of recombinant protein technology in Silicon Valley about 50 years ago. Recent improvements in the production, purification, and transport of RNA to cells have paved the way for the development of RNA-based therapies for a wide range of uses. RNA therapies are a rapidly growing class of medications that will revolutionize the treatment of numerous diseases and enable personalized therapy. These medications are inexpensive, easy to make, and can target routes that were previously unreachable. Small biotech businesses and university groups can quickly produce new and tailored RNA structures, making it a breakthrough medicinal tool.

Rising awareness and development of novel drugs

Multinational healthcare organizations raise awareness and assist in the development of novel remedies for a variety of ailments. Private institutes participating in conducting trials by supporting research institutes and pharmaceutical companies, such as the California Institute of Regenerative Medicine and the ALS Association, are predicted to considerably fuel sector expansion. Furthermore, government initiatives aimed at accelerating the development of medication delivery systems in order to lower illness burdens contribute to industrial development.

Antisense and RNAi therapies can be used to treat a variety of disorders that impact the cell growth cycle and target nucleic acids. The ability of miRNA to restore gene expression and correct protein production, consequently impacting industrial advancement, is receiving a lot of attention. Research into the use of various pathways to deliver the intended impact of the candidate moiety before it is removed from the blood is expected to boost sector expansion.

The constraints involved with drug distribution, on the other hand, are projected to hamper expansion to some extent.

The Global RNA Therapeutics Market is segmented based on technology, route of administration indication and region.

On the basis of Technology, the Global RNA Therapeutics Market is segmented into RNA Interference and Antisense RNA. Based on Route of administration, the target market is segmented into Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Topical Delivery and Others. Based on Indication, the target market is segmented into Oncology, CVDs, Respiratory Disorders, Neurological Disorders, Infectious Disorders and Others.

Regional Insights:

On region the Global RNA Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The RNA therapeutics market was dominated by North America, followed by Europe, Asia Pacific, Latin America, and the Middle East and Africa. The growing development of structure-based drug designs, growing academic and government investments in genomics and proteomics research, high life science research funding, high biopharmaceutical R&D expenditure, and greater adoption of advanced technologies in North America can all be attributed to this market segment's large share. Another important reason contributing to this market segment's significant share is the presence of a large number of global companies in this area. North America now holds the largest revenue share of the market because much of the research and development work is centred in that region. However, over the forecast period, Asia Pacific and other growing regions would gradually catch up.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global RNA Therapeutics Market report based on technology, route of administration, indication and region.

Global RNA Therapeutics Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

Some of the companies which are currently dominating the market are Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US). Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market.

• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• Illumina, Inc.
• QIAGEN N.V.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation